AT340892B - Verfahren zur herstellung von neuen 1-aminomethyl-1-cycloalkanessigsauren und deren estern sowie salzen - Google Patents

Verfahren zur herstellung von neuen 1-aminomethyl-1-cycloalkanessigsauren und deren estern sowie salzen

Info

Publication number
AT340892B
AT340892B AT975075A AT975075A AT340892B AT 340892 B AT340892 B AT 340892B AT 975075 A AT975075 A AT 975075A AT 975075 A AT975075 A AT 975075A AT 340892 B AT340892 B AT 340892B
Authority
AT
Austria
Prior art keywords
cycloalkanethic
aminomethyl
esters
acids
salt
Prior art date
Application number
AT975075A
Other languages
English (en)
Other versions
ATA975075A (de
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=5934284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT340892(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ATA975075A publication Critical patent/ATA975075A/de
Application granted granted Critical
Publication of AT340892B publication Critical patent/AT340892B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT975075A 1974-12-21 1975-12-22 Verfahren zur herstellung von neuen 1-aminomethyl-1-cycloalkanessigsauren und deren estern sowie salzen AT340892B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2460891A DE2460891C2 (de) 1974-12-21 1974-12-21 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (2)

Publication Number Publication Date
ATA975075A ATA975075A (de) 1977-05-15
AT340892B true AT340892B (de) 1978-01-10

Family

ID=5934284

Family Applications (1)

Application Number Title Priority Date Filing Date
AT975075A AT340892B (de) 1974-12-21 1975-12-22 Verfahren zur herstellung von neuen 1-aminomethyl-1-cycloalkanessigsauren und deren estern sowie salzen

Country Status (16)

Country Link
US (1) US4024175A (de)
JP (1) JPS5324064B2 (de)
AT (1) AT340892B (de)
BE (1) BE836835A (de)
CA (1) CA1052811A (de)
CH (3) CH612665A5 (de)
DE (1) DE2460891C2 (de)
DK (1) DK147706C (de)
ES (1) ES443723A1 (de)
FI (1) FI62282C (de)
FR (1) FR2294697A1 (de)
GB (1) GB1465229A (de)
IE (1) IE42382B1 (de)
LU (1) LU74058A1 (de)
NL (1) NL181006C (de)
SE (1) SE423385B (de)

Families Citing this family (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2611690A1 (de) * 1976-03-19 1977-09-22 Goedecke Ag Cyclische sulfonyloxyimide
JPS5776189U (de) * 1980-10-28 1982-05-11
JPS6152583U (de) * 1984-09-11 1986-04-09
JPS61139881U (de) * 1985-02-21 1986-08-29
US4876279A (en) * 1986-05-05 1989-10-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
US4960931A (en) * 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
YU162789A (en) * 1988-09-01 1990-12-31 Lonza Ag 2-aza-4-(alcoxycarbonyl) spiro/4,5/decan-3-ones
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5132451A (en) * 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
PH27359A (en) * 1989-08-25 1993-06-21 Warner Lambert Co Process for cyclic amino acid anticonvulsant compounds
DE3928184A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
DE3928182A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von gabapentin
US5319135A (en) * 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
FI905584A7 (fi) * 1989-11-16 1991-05-17 Lonza Ag Menetelmä 1-(aminometyyli)sykloheksaanietikkahapon valmistamiseksi
US5260467A (en) * 1989-11-16 1993-11-09 Pfizer Inc. Glutaric acid derivatives and preparation thereof
US5136091A (en) * 1989-11-16 1992-08-04 Lonza Ltd. Process for the production of 1-(aminomethyl) cyclohexane acetic acid
GB8925933D0 (en) * 1989-11-16 1990-01-04 Pfizer Ltd Glutaric acid derivatives and preparation thereof
US5149870A (en) * 1989-11-16 1992-09-22 Lonza Ltd. Process for the production of 1-(aminomethyl)cyclohexane acetic acid
US5157138A (en) * 1989-11-16 1992-10-20 Pfizer, Inc. Glutaric acid derivatives and preparation thereof
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
DE69712877T2 (de) * 1996-02-07 2002-11-14 Warner-Lambert Co., Morris Plains Zyklischaminosäure als pharmazeutische mittel
JP2000506862A (ja) * 1996-03-14 2000-06-06 ワーナー―ランバート・コンパニー 医薬としての新規な架橋環状アミノ酸
SK283295B6 (sk) * 1996-03-14 2003-05-02 Warner-Lambert Company Substituovaná cyklická aminokyselina, jej použitie a farmaceutický prostriedok na jej báze
NZ332762A (en) 1996-07-24 2000-09-29 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
JP2002514187A (ja) * 1996-10-23 2002-05-14 ワーナー―ランバート・コンパニー 薬剤としての置換γ―アミノ酪酸
US6255526B1 (en) 1996-12-24 2001-07-03 Teva Pharmaceutical Industries Ltd. Preparation of gabapentin
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
HRP980342A2 (en) * 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
US6194459B1 (en) 1997-08-19 2001-02-27 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants
HU226165B1 (en) * 1997-09-08 2008-05-28 Warner Lambert Co Analgesic compositions comprising anti-epileptic compounds and non-steroid anti-inflammatory dr4gs
US6294690B1 (en) 1997-10-07 2001-09-25 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
CA2303244C (en) * 1997-10-27 2005-12-06 Warner-Lambert Company Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
US6984659B2 (en) * 1997-11-18 2006-01-10 Klinikum Der Albert-Ludwigs Universitaet 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
KR20010033153A (ko) 1997-12-16 2001-04-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 4(3)-치환-4(3)-아미노메틸-(티오)피란 또는 -피페리딘유도체(=가바펜틴 동족체), 그의 제법 및 신경 질환 치료용도
JP2002508362A (ja) * 1997-12-16 2002-03-19 ワーナー−ランバート・カンパニー １−置換−１−アミノメチル−シクロアルカン誘導体（＝ガバペンチン類縁体）、その製造および神経学的疾患の治療におけるその使用
TR200001794T2 (tr) 1997-12-16 2000-10-23 Warner-Lambert Company Farmasötik maddeler olarak yeni aminler
CA2309354A1 (en) * 1998-01-23 1999-07-29 Leslie Magnus-Miller Gabapentin and its derivatives for the treatment of muscular and skeletal pain
EP0974351A3 (de) * 1998-04-24 2000-12-13 Jouveinal Arzneimittel zur Vorbeugung und Behandlung von Magendarmschäden
NZ508015A (en) 1998-05-15 2003-11-28 Warner Lambert Co Stabilized pharmaceutical preparations of gamma- aminobutyric acid derivatives and process for preparing the same
AU769038B2 (en) * 1998-05-15 2004-01-15 Warner-Lambert Company Llc Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
ES2137137B1 (es) * 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
WO1999061424A1 (en) 1998-05-26 1999-12-02 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
ITMI981535A1 (it) * 1998-07-03 2000-01-03 Zambon Spa Processo per la preparazione di gabapentina
US20030045500A1 (en) * 1998-07-09 2003-03-06 Leslie Magnus Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
FR2781793B1 (fr) 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
HU225502B1 (en) * 1998-12-29 2007-01-29 Richter Gedeon Vegyeszet Process for producing 1-(amino-metyl)-cyclohexene-acetic-acid and intermediates
IT1311984B1 (it) * 1999-03-26 2002-03-22 Bioindustria Lab Italiano Medi Procedimento per la preparzione di gabapentin.
CA2370030C (en) * 1999-04-09 2007-08-14 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
BR0011039A (pt) * 1999-05-28 2002-02-26 Warner Lambert Co Análogos de gaba substituìdos com 3-heteroarilalquila
US6710190B1 (en) * 1999-05-28 2004-03-23 Warner-Lambert Company 3-heteroarylalkyl substituted gaba analogs
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
CA2374755C (en) * 1999-06-10 2010-03-30 Warner-Lambert Company Mono- and disubstituted 3-propyl gamma-aminobutyric acids
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
HN2000000224A (es) 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB2362646A (en) * 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
ES2193008T3 (es) 2000-06-16 2004-07-01 Teva Pharmaceutical Industries Ltd. Gabapentina estable que contiene mas de 20 ppm de iones de cloro.
EP1384473A1 (de) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stabiles Gabapentin das mehr als 20 ppm Chlor enthält
HRP20030002A2 (en) * 2000-06-16 2005-10-31 Teva Pharmaceutical Industries Ltd. STABLE GABAPENTIN HAVING pH WITHIN A CONTROLLED RANGE
KR100785182B1 (ko) * 2000-06-26 2007-12-11 워너-램버트 캄파니 엘엘씨 수면 장애를 위한 가바펜틴 유사체
GB2364049A (en) * 2000-06-28 2002-01-16 Warner Lambert Co Cyclic ketones and their use in the synthesis of amino acids
PL361424A1 (en) * 2000-09-14 2004-10-04 Grünenthal GmbH ß-THIO-AMINO ACIDS
US6992076B2 (en) * 2000-10-06 2006-01-31 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US6900192B2 (en) * 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
US6620829B2 (en) * 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
IT1319234B1 (it) * 2000-10-23 2003-09-26 Zambon Spa Processo di preparazione di gabapentina.
GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
SK6372003A3 (en) * 2000-11-02 2003-12-02 Teva Pharma Improved process for production of gabapentin intermediate
JP2004514699A (ja) * 2000-11-30 2004-05-20 ファイザー・プロダクツ・インク Ｇａｂａアゴニストおよびソルビトールデヒドロゲナーゼ阻害剤の組合せ
SK6092003A3 (en) * 2000-11-30 2004-07-07 Pfizer Prod Inc Combination of GABA agonists and aldosereductase inhibitors
IT1319674B1 (it) * 2000-12-01 2003-10-23 Erregierre Spa Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
JP2004524339A (ja) * 2001-03-16 2004-08-12 ソルケム イタリアーナ エス．ピー．エイ． 環状アミノ酸の調製方法
ITMI20011132A1 (it) 2001-05-29 2002-11-29 Procos Spa Procedimento per la preparazione dell'acido 1-amminometil-1-cicloesanacetico
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
CA2449729C (en) 2001-06-11 2009-11-03 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
EP1412324A4 (de) * 2001-06-11 2004-09-29 Xenoport Inc Aminosäurekonjugate, die anhaltende systemische konzentrationen von gaba-analoga ergeben
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
IL144066A0 (en) * 2001-06-28 2002-04-21 Bromine Compounds Ltd Process for the preparation of 1,1-cyclohexane diacetic monoamide
ITMI20011772A1 (it) 2001-08-10 2003-02-10 A M S A Anonima Materie Sint E Processo per la preparazione della 2,5-bis-(2,2,2-trifluoroetossi)-n-(2-piperidilmetil)-benzamide(flecainide)
DK1423168T3 (da) 2001-09-03 2006-05-15 Newron Pharm Spa Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse
US6800782B2 (en) * 2001-10-09 2004-10-05 Warner-Lambert Co. Anhydrous crystalline forms of gabapentin
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
IL162028A0 (en) * 2002-01-31 2005-11-20 Warner Lambert Co Alpha 2 delta ligands to treat tinnitus
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2003077902A1 (en) * 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US7026351B2 (en) * 2002-03-20 2006-04-11 Xenoport, Inc. Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof
CA2478471A1 (en) * 2002-04-16 2003-10-30 Taro Pharmaceutical Industries Ltd. Process for preparing gabapentin
WO2003094842A2 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
WO2003099338A2 (en) * 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
WO2004002462A2 (en) * 2002-06-27 2004-01-08 Warner-Lambert Company Llc Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder
CA2395931A1 (en) * 2002-08-07 2004-02-07 Bernard Charles Sherman Solid compositions comprising gabapentin having improved stability
US7053122B2 (en) * 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US20040092591A1 (en) * 2002-08-15 2004-05-13 Blakemore David Clive Therapeutic use of fused bicyclic or tricyclic amino acids
US20040092522A1 (en) * 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US20040092498A1 (en) * 2002-08-16 2004-05-13 David Blakemore Substituted glycine derivatives for use as medicaments
ITMI20022071A1 (it) * 2002-10-01 2004-04-02 Erregierre Spa Processo di sintesi dell'acido 1-(aminometil)cicloesanacetico cloridato.
US7659305B2 (en) * 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
US7196216B2 (en) * 2002-11-18 2007-03-27 Nicholas Piramal India Limited Process for preparation of Gabapentin
CA2506564C (en) * 2002-11-20 2011-03-29 Hikal Ltd. An improved process for the preparation of gabalactam
WO2004053192A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
WO2004052360A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
AU2003283718A1 (en) * 2002-12-13 2004-07-09 Warner-Lambert Company Llc Gabapentin analogues for fibromyalgia and other related disorders
JP2006511604A (ja) * 2002-12-13 2006-04-06 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 線維筋痛症及び関連する他の障害の治療のためのプレガバリン及びその誘導体
US20040180958A1 (en) * 2002-12-13 2004-09-16 Taylor Charles Price Method of treatment
CN101862317A (zh) 2002-12-13 2010-10-20 沃尼尔·朗伯有限责任公司 用于治疗纤维肌痛和其它疾病的普加巴林衍生物
JP2006511606A (ja) 2002-12-13 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 下部尿路症状を治療するα−２−δリガンド
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
GB0301143D0 (en) * 2003-01-17 2003-02-19 Amedis Pharm Ltd Compounds and their use
KR100743800B1 (ko) * 2003-01-22 2007-07-30 워너-램버트 캄파니 엘엘씨 사이클로프로필 베타-아미노산 유도체
BRPI0408110A (pt) * 2003-03-07 2006-03-01 Warner Lambert Co derivados de beta-aminoácido substituìdos com tetrazol e oxadiazolona
EP1622603A4 (de) * 2003-03-25 2010-03-24 Kiel Lab Inc Phenolsäuresalze von gabapentin in festen dosierformen und anwendungsverfahren
WO2004093867A2 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use
WO2004093866A1 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Process for preparing phenolic acid salts of gabapentin
EP1608357A4 (de) * 2003-03-31 2008-03-26 Xenoport Inc Behandlung oder prävention von hitzewallungen unter verwendung von prodrugs von gaba-analoga
US20040214893A1 (en) * 2003-04-11 2004-10-28 Matthew Peterson Gabapentin compositions
ITMI20030825A1 (it) * 2003-04-18 2004-10-19 Farchemia Srl Procedimento per la preparazione di gabapentin esente da
EP1615875A2 (de) * 2003-04-21 2006-01-18 Matrix Laboratories Limited Verfahren zur herstellung von gabapentin form-ii
JP2006528676A (ja) * 2003-05-16 2006-12-21 ファイザー・プロダクツ・インク 非定形型抗精神病薬と、ｇａｂａ調節薬及び／又は抗痙攣薬の治療上の組合せ
WO2004111256A1 (en) * 2003-06-19 2004-12-23 Pfizer Products Inc. Biocatalytic preparation of 1-cyanocyclohexaneacetic acid
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
EP1680125A1 (de) * 2003-07-02 2006-07-19 Warner-Lambert Company LLC Kombination eines allosterischen hemmers der matrix metalloproteinase 13 und eines liganden des alpha-2-delta rezeptors
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
WO2005046566A2 (en) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Stable gabapentin containing composition
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
JP2007505149A (ja) * 2003-09-11 2007-03-08 ゼノポート，インコーポレイティド ギャバ類似体のプロドラッグを用いる尿失禁の治療および／あるいは予防
EP1675582A1 (de) * 2003-09-12 2006-07-05 Warner-Lambert Company LLC Kombination aus einem alpha-2-delta-liganden und einem ssri und/oder snri zur behandlung von depressionen und angstzuständen
EP1663398B1 (de) * 2003-09-12 2009-11-25 Pfizer Limited Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
SG146643A1 (en) * 2003-09-17 2008-10-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
KR101096480B1 (ko) * 2003-10-14 2011-12-20 제노포트 인코포레이티드 감마-아미노부티르산 유사체의 결정질 형태
ITMI20032165A1 (it) * 2003-11-11 2005-05-12 Zambon Spa Processo di preparazione di gabapentina
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
CA2553291A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. Combination of .gamma.-aminobutyric acid modulators and 5-ht1b receptor antagonists
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
EP1763503A1 (de) * 2004-03-17 2007-03-21 Hikal Limited 4-t-butylgabapentin und dessen synthese
ITMI20040579A1 (it) * 2004-03-25 2004-06-25 Zambon Spa Processo di preparazione di gabapentina
EP1737473A4 (de) * 2004-04-19 2009-08-26 Noven Therapeutics Llc Lithium-kombinationen und relevante verwendungen
AU2005256944A1 (en) * 2004-06-09 2006-01-05 Pfizer Inc. Use of reboxetine for the treatment of pain
GB0416228D0 (en) * 2004-07-20 2004-08-25 Sandoz Ind Products S A Process for the preparation of gabapentin
GB0419849D0 (en) * 2004-09-07 2004-10-13 Pfizer Ltd Pharmaceutical combination
US20080096965A1 (en) * 2004-09-10 2008-04-24 Newron Pharmaceuticals S.P.A. (Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators
WO2006050514A1 (en) 2004-11-04 2006-05-11 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
CA2623535A1 (en) * 2005-09-23 2007-04-19 Janssen Pharmaceutica N.V. Hexahydro cyclooctyl pyrazole cannabinoid modulators
BRPI0616402A2 (pt) * 2005-09-23 2011-06-21 Janssen Pharmaceutica Nv moduladores de canabinóide de hexaidro-cicloeptapirazol
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
KR20080050511A (ko) 2005-09-23 2008-06-05 얀센 파마슈티카 엔.브이. 테트라하이드로-사이클로펜틸 피라졸 카나비노이드모듈레이터
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
EP2377530A3 (de) 2005-10-21 2012-06-20 Braincells, Inc. Modulation von Neurogenese durch PDE-Hemmung
EP1942879A1 (de) * 2005-10-31 2008-07-16 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
WO2007092456A2 (en) * 2006-02-03 2007-08-16 Rolls-Royce Corporation Gas turbine engine fuel system with fuel metering valve
EP1820502A1 (de) 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Wirkstoffzusammensetzungen enthaltend Azolycarbinolderivate
US7795294B2 (en) * 2006-02-14 2010-09-14 Janssen Pharmaceutica N.V. Tetrahydro-2H-indazole pyrazole cannabinoid modulators
RU2008135907A (ru) * 2006-03-06 2010-04-20 Пфайзер Продактс Инк. (Us) Альфа-2-дельта лиганды для невосстановительного сна
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007112402A1 (en) * 2006-03-27 2007-10-04 Janssen Pharmaceutica N.V. Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
US7442834B2 (en) * 2006-06-12 2008-10-28 Zhejiang Chiral Medicine Chemicals Co., Ltd. Process suitable for industrial scale production of gabapentin
CA2660769C (en) * 2006-06-30 2013-12-03 Zach System S.P.A. Process for preparing gabapentin
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
MX2009006080A (es) * 2006-12-08 2009-07-14 Xenoport Inc Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades.
JP5308350B2 (ja) 2006-12-22 2013-10-09 レコルダーティ アイルランド リミテッド α２δリガンドおよびＮＳＡＩＤを用いた下部尿路機能障害の併用療法
CN101631768A (zh) * 2007-03-15 2010-01-20 太阳医药高级研究有限公司 新型前药
WO2008157408A2 (en) * 2007-06-15 2008-12-24 Xenoport, Inc. Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090062392A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched gabapentin
US20090118365A1 (en) * 2007-11-06 2009-05-07 Xenoport, Inc Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
EP2250148B1 (de) * 2008-01-25 2016-08-17 XenoPort, Inc. Kristalline form von kalziumsalzen von (3s)-aminomethyl-5-methylhexansäuren und anwendungsverfahren
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
ES2601852T3 (es) * 2008-01-25 2017-02-16 Xenoport, Inc. Forma cristalina de sales de calcio de ácidos (3S)-aminometil-5-metil-hexanoicos y métodos de uso
EP2116539A1 (de) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-Aryl-3-Amino-alkoxy-pyrazole als Sigma-Liganden zur Verbesserung der analgetischen Wirkung von Opioiden und zur Schwächung der Abhängigkeit davon
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
KR101810246B1 (ko) 2008-10-08 2017-12-18 엑스진 파마슈티컬 인크. Ｇａｂａ 접합체 및 그의 사용 방법
WO2010099200A1 (en) 2009-02-24 2010-09-02 Nektar Therapeutics Oligomer-amino acid conjugates
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20110130454A1 (en) * 2009-11-24 2011-06-02 Xenoport, Inc. Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
EP2353591A1 (de) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma-Liganden zur Verstärkung der analgesischen Wirkung von Opioden und Opiaten bei postoperativem Schmerz und zur Schwächung der Abhängigkeit davon
EP2368872A1 (de) 2010-03-25 2011-09-28 Serichim S.r.l. Verfahren zur Herstellung von Gabapentin
EP2388005A1 (de) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma-Liganden zur Vorbeugung und/oder Behandlung von Erbrechen infolge von Chemotherapie oder Strahlentherapie
WO2011151708A1 (en) 2010-06-01 2011-12-08 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
US8431739B2 (en) 2010-06-14 2013-04-30 Divi's Laboratories, Ltd. Process for the preparation of gabapentin
JP5786714B2 (ja) 2010-07-30 2015-09-30 東レ株式会社 神経障害性疼痛の治療剤又は予防剤
EP2415471A1 (de) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Sigmaliganden bei opioidinduzierter Hyperalgesie
JP2013216580A (ja) * 2010-08-06 2013-10-24 Kyorin Pharmaceutical Co Ltd ビシクロ［２．２．２］オクチルアミン誘導体の製造方法
EP2524694A1 (de) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Sigmaliganden bei Schmerz im Zusammenhang mit Typ-2-Diabetes
EP2530072A1 (de) 2011-06-03 2012-12-05 Lacer, S.A. Neue Verbindungen, deren Synthese und Verwendung bei der Schmerzbehandlung
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
ITMI20131757A1 (it) 2013-10-22 2015-04-23 Zach System Spa Processo di preparazione di gabapentina
JPWO2015064453A1 (ja) 2013-11-01 2017-03-09 株式会社糖鎖工学研究所 チオール基を有するｄ−体またはｌ−体アミノ酸誘導体の製造方法
CN105873578A (zh) 2013-12-17 2016-08-17 埃斯蒂维实验室股份有限公司 血清素－去甲肾上腺素再摄取抑制剂(SNRIs)和σ受体配体组合物
WO2015091505A1 (en) 2013-12-17 2015-06-25 Laboratorios Del Dr. Esteve, S.A. Gabapentinoids and sigma receptor ligands combinations
WO2015144825A1 (en) 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
MA49114A (fr) 2016-12-16 2020-03-25 Idorsia Pharmaceuticals Ltd Combinaison pharmaceutique comprenant un bloqueur de canal calcique de type t
MX384760B (es) 2018-07-04 2025-03-14 Federico Amezcua Amezcua Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.
US10399926B1 (en) 2018-08-01 2019-09-03 Divi's Laboratories Ltd. Process for the preparation of gabapentin
KR102651652B1 (ko) 2018-10-11 2024-03-26 사니핏 테라퓨틱스 에스.에이. 이소성 석회화의 치료를 위한 이노시톨 포스페이트
WO2021079887A1 (ja) 2019-10-25 2021-04-29 国立大学法人京都大学 タウオパチーの予防又は治療剤
KR20220163384A (ko) 2020-03-04 2022-12-09 플레오파마, 엘.엘.씨. 칸나비스 사용 장애를 치료하고 칸나비노이드 금단을 완화하기 위한 방법 및 조성물
EP4015494A1 (de) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Verfahren zur herstellung von löslichen salzen von inositolphosphaten
GB2625579A (en) 2022-12-21 2024-06-26 Novumgen Ltd An orally disintegrating tablet containing gabapentin or pharmaceutically acceptable salts thereof and the process of preparing the same

Also Published As

Publication number Publication date
FI753613A7 (de) 1976-06-22
ES443723A1 (es) 1977-04-16
NL181006B (nl) 1987-01-02
IE42382L (en) 1976-06-21
SE7514442L (sv) 1976-06-22
JPS5324064B2 (de) 1978-07-18
FI62282B (fi) 1982-08-31
DE2460891C2 (de) 1982-09-23
DE2460891A1 (de) 1976-07-01
DK147706C (da) 1985-05-13
BE836835A (fr) 1976-06-18
CH612665A5 (de) 1979-08-15
FI62282C (fi) 1982-12-10
SE423385B (sv) 1982-05-03
DK147706B (da) 1984-11-19
DK581475A (da) 1976-01-22
GB1465229A (en) 1977-02-23
FR2294697A1 (fr) 1976-07-16
IE42382B1 (en) 1980-07-30
CA1052811A (en) 1979-04-17
CH612666A5 (de) 1979-08-15
ATA975075A (de) 1977-05-15
NL7514900A (nl) 1976-06-23
US4024175A (en) 1977-05-17
CH612664A5 (de) 1979-08-15
AU8774175A (en) 1977-06-23
FR2294697B1 (de) 1978-07-28
JPS5188940A (de) 1976-08-04
NL181006C (nl) 1987-06-01
LU74058A1 (de) 1976-07-20

Similar Documents

Publication Publication Date Title
AT340892B (de) Verfahren zur herstellung von neuen 1-aminomethyl-1-cycloalkanessigsauren und deren estern sowie salzen
AT341506B (de) Verfahren zur herstellung von neuen substituierten phenylessigsauren und ihren estern
ATA693675A (de) Verfahren zur herstellung von neuen fusidinsaurederivaten, sowie deren salzen und estern
AT328449B (de) Verfahren zur herstellung von neuen chinolincarbonsaure- (2) -verbindungen und deren estern und salzen
AT327903B (de) Verfahren zur herstellung von neuen estern und amiden von pyridin-2-carbonsauren
AT326148B (de) Verfahren zur herstellung von neuen carboxyphenylalkylphosphinsäuren sowie deren estern
AT329181B (de) Verfahren zur herstellung von neuen 7-acylamido-3-fluor-3-cephem-4-carbonsaureestern und -sauren
AT299909B (de) Verfahren zur Herstellung von neuen Sulfamylanthranilsäuren sowie deren Salzen und Estern
AT335439B (de) Verfahren zur herstellung von neuen phenoxyalkylcarbonsauren und von deren estern
AT326629B (de) Verfahren zur herstellung von neuen 5-sulfamoylbenzoesäuren, sowie von deren salzen und estern
ATA953474A (de) Verfahren zur herstellung von neuen acylaminocephemcarbonsauren und von deren salzen und estern
AT344161B (de) Verfahren zur herstellung von neuen phenoxyalkancarbonsaeureamiden von thiazolidincarbonsaeuren und ihren salzen
ATA638275A (de) Verfahren zur herstellung von neuen cinnolin-3-yl-carbonsauren und von deren salzen
AT308733B (de) Verfahren zur Herstellung von neuen 9,10-Dihydro-9,10-dioxo-anthracen-2-carbonsäuren sowie deren Salzen und Estern
AT341505B (de) Verfahren zur herstellung von neuen phenylalkansauren, deren estern oder amiden und deren salzen
AT337678B (de) Verfahren zur herstellung von neuen indanylessigsauren und deren metallsalzen
ATA424575A (de) Verfahren zur herstellung von neuen aminoalkylphenoxyalkansaeuren, deren estern und salzen
AT335601B (de) Verfahren zur herstellung von 7-amino-3-cephem-4-carbonsauren und deren estern und salzen
ATA902277A (de) Verfahren zur herstellung von neuen estern von phenylaethylaminderivaten und von deren saeure- additionssalzen
ATA125278A (de) Verfahren zur herstellung von neuen amino- alkylphenoxyalkansaeuren, deren estern und salzen
AT320857B (de) Verfahren zur Herstellung von neuen α-Carboxy-2-thienylmethylpenicillinen und α-Carboxy-2-thienylmethylcephalosporinen sowie deren Estern und basischen Salzen
ATA125178A (de) Verfahren zur herstellung von neuen amino- alkylphenoxyalkansaeuren und deren estern und salzen
AT326105B (de) Verfahren zur herstellung von neuen 5-sulfamoylbenzoesauren, sowie von deren salzen und estern
ATA549776A (de) Verfahren zur herstellung von neuen 1-amino-alkyl-2-aryl-cyclohexanolen und deren estern
ATA995774A (de) Verfahren zur herstellung von neuen diphenoxyessigsauren und deren estern sowie deren salzen

Legal Events

Date Code Title Description
SZA Application filed for a certificate of protection

Free format text: SZ98/94, 941220

ELA Expired due to lapse of time
EZF Grant of a certificate of protection

Free format text: SZ 98/94, 941220, EXPIRES:20000515